Better MRSA Strategy: Treat All ICU Patients
This study, he said in an interview, should change practice. 'This study shows that testing people for MRSA and isolating them is not an effective way to control MRSA in the hospital, which we've been arguing all along."
In an interview, however, Edmond said he is "a little worried, because I think that widespread use of mupirocin will likely lead to development of a lot of resistance." His hospital uses routine chlorhexidine baths in the ICU, but not mupirocin.
MRSA colonization is a major target in quality measurement because bloodstream infections are common and are lethal in more than 20% of cases. Increased length of stay can add costs of as much as $30,000 per patient.
A decade ago, the CDC estimated 90,000 invasive MRSA infections, most of them acquired in hospitals, with 19,000 deaths per year. Hand hygiene and other strategies have reduced those rates by 28% between 2005 and 2008 and again 28% in 2011.
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- How Top-Ranked MA Plans Earn Their Stars
- WellPoint Dominates Nearly Half of Markets, AMA Says
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- How Hospitals Can Become 'Upstreamists'
- Providers Ask HHS to Address EHR Interoperability Barriers
- 16 Medicare Advantage Plans Earn 5-Star Ratings
- The Drug Price Reform Debate
- CMS' new investment model will help ACOs with health IT
- Ebola: A Call for Designated Hospitals